SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2407Now we know it is for >50% PDL1 expression, where Keyt become SOC. clinicaltMiljenko Zuanic15/3/2018
2406Fasinumab for pain in OS (safety p3): clinicaltrials.gov In May-2017 they addeMiljenko Zuanic-5/3/2018
2405FUCxx idiots (from regn) on CC. Why they do not PR (or IR-letter) "open remMiljenko Zuanic-5/3/2018
24041Q result: newsroom.regeneron.comMiljenko Zuanic-5/3/2018
2403Sanofi general meeting,: sanofi.com If cemiplimab is highly effective in CutaneMiljenko Zuanic-5/2/2018
2402I hope some other PBMs join in...Felix B-5/2/2018
2401Thanks for sharing!Felix B-5/2/2018
2400Science from AACR 2018 Lag-3: files.shareholder.com CTLA-4: files.shareholder.cMiljenko Zuanic-5/1/2018
2399jci.org This may be long (and insecure) shot for Kavzara and similar compounds.Miljenko Zuanic-5/1/2018
2398RE:AD This is bit old, but has very illustrative data sets: dermatologyupdate.cMiljenko Zuanic-5/1/2018
2397cnbc.com Definitely, peak sale numbers for Praluent (and Repatha) will be adjusMiljenko Zuanic-5/1/2018
2396It is bit odd,... they are trying to build marketing because manufacturing cost Miljenko Zuanic-4/30/2018
2395RTH258: It's unusual to have "pre-specified" secondary endpoints rDewDiligence_on_SI-4/30/2018
2394RTH258 globenewswire.comMiljenko Zuanic-4/30/2018
2393Cemiplimab BLA accepted by FDA, priority PDUFA is 10-28-2018.Miljenko Zuanic-4/30/2018
2392RE: Is there any option left for possibility of positive surprise??? SNY mentioMiljenko Zuanic-4/27/2018
2391RE: D+P+K 1Q sale (by SNY): What a MEDIOCRE and DEBILITATING performance by REGNMiljenko Zuanic-4/27/2018
2390Pocking into eye is not FUN! So, Novartis may present real competitor! ManufactMiljenko Zuanic-4/26/2018
2389[Semi-OT]—During RVNC's Investor Day last week, RVNC cited the uptake of EylDewDiligence_on_SI-4/26/2018
2388Lucentis US 1Q sale was 393 CHF (at 0.95 currency conversion), $414M. ContinuousMiljenko Zuanic-4/26/2018
2387Reminds me of NFL coaching coral... round and round they go....I am not losing aFelix B-4/24/2018
2386Unproductive, time wasting, Zerhouni is out; endpts.com Now, the Qs are will JRMiljenko Zuanic-4/24/2018
2385Novartis 1Q report: Lucentis ex-US sale of $520m, 17% growth v 1Q2017 (10% grow Miljenko Zuanic-4/19/2018
2384Medicare part B, is price control for biologic advancing? politico.com <AnoMiljenko Zuanic-4/16/2018
2383This may help: seekingalpha.comMiljenko Zuanic-4/11/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News